October 2017, Volume 3, Issue 12

October 2017

Volume 3, Issue 12

This issue features a look at hospital ranking systems, the risks and benefits of opioids for pain management, and more.

Table of Contents

October 2017 Issue

With a Little Help From My Friends

Sunday, October 1st, 2017
“Do you have a second to talk about a case?” It’s a line heard on phones and in offices the world over. A colleague, stumped...

How would you treat a pregnant woman with iron deficiency who has undergone bariatric...

Sunday, October 1st, 2017
Here’s how readers responded to a You Make the Call question about a pregnant woman with iron deficiency who has undergone bariatric surgery. Disclaimer: ASH...

October 2017 Issue

ASH Selects Hematologists for 2017 Visitor Training Program, New MIPS Reporting Tool Available, and...

Sunday, October 1st, 2017
ASH Selects Hematologists from Developing Countries to Participate in Training Program The American Society of Hematology (ASH) selected 25 hematologists and medical professionals from developing...

UC San Diego Researchers Receive Grant for CAR T-cell Therapy, New President at Seidman...

Sunday, October 1st, 2017
Theodoros N. Teknos Appointed President and Scientific Officer of University Hospitals Seidman Cancer Center Theodoros N. Teknos, MD, has been named the president and scientific...

October 2017 Issue

The Pains of Opioid Prescribing

Sunday, October 1st, 2017
The United States is in a state of emergency: The Centers for Disease Control and Prevention (CDC) estimates that 91 Americans die each day...

The Rank Tank

Sunday, October 1st, 2017
Are public health-care ratings an indicator of quality or of popularity? Each summer, U.S. News & World Report releases its list of the best hospitals...

Pulling Back the Curtain: Brian G. M. Durie, MD

Sunday, October 1st, 2017
In this edition, Brian G. M. Durie, MD, shares how his father’s battle with tuberculosis led to his interest in medicine, and how his...

October 2017 Issue

How I Treat in Brief: Double-Hit Lymphoma

Sunday, October 1st, 2017
This month, Jonathan W. Friedberg, MD, MMSc, discusses the diagnosis and treatment of patients with double-hit lymphoma. This material was repurposed from “How I Treat...

What are treatment options for a pregnant woman with iron deficiency who has had...

Sunday, October 1st, 2017
This month Michael Auerbach, MD, discusses treatment options for a pregnant woman with iron deficiency who has had bariatric surgery. And don't forget to check...

October 2017 Issue

First CAR T-Cell Therapy for Pediatric Leukemia Gains FDA Approval

Sunday, October 1st, 2017
The U.S. Food and Drug Administration (FDA) approved the chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel for the treatment of pediatric and young adult...

Dasatinib Receives Priority Review for New CML Indications

Sunday, October 1st, 2017
The U.S. Food and Drug Administration (FDA) granted priority review to dasatinib, a tyrosine kinase inhibitor, for pediatric patients with chronic myeloid leukemia (CML). The...

FDA Approves Enasidenib for Patients With Relapsed/Refractory AML

Sunday, October 1st, 2017
The U.S. Food and Drug Administration (FDA) approved enasidenib, an isocitrate dehydrogenase-2 (IDH2) inhibitor, for adults with relapsed/refractory IDH2-mutated acute myeloid leukemia (AML). The...

Ibrutinib Becomes First FDA-Approved Therapy for Chronic GVHD

Sunday, October 1st, 2017
The U.S. Food and Drug Administration approved ibrutinib, a Bruton tyrosine kinase inhibitor, for secondline treatment of adults with chronic graft-versus-host disease (cGVHD), making...

Can a Post-AHCT, High-Intensity Exercise Program Improve Quality of Life in Patients With Myeloma?

Sunday, October 1st, 2017
Patients with myeloma who undergo autologous hematopoietic cell transplantation (AHCT) may experience a decline in health-related quality of life (HRQoL). Although exercise has been...
WIB_icon

Fertility Issues in Patients With Inherited Bone Marrow Failure Syndromes

Sunday, October 1st, 2017
More patients with inherited bone marrow failure syndromes (IBMFS) are surviving to adulthood. As they do, they face barriers to pregnancy. It is still...
WIB_icon

Do Patients With Lower-Risk MDS Benefit From Low-Dose Hypomethylating Agents?

Sunday, October 1st, 2017
The hypomethylating agents (HMAs) azacitidine and decitabine have been shown to improve survival and/or delay disease progression in patients with higher-risk myelodysplastic syndromes (MDS),...
WIB_icon

Patients With Sickle Cell Disease at Increased Risk for Hematologic Cancers, Especially Leukemia

Sunday, October 1st, 2017
As the treatment of patients with sickle cell disease (SCD) has improved, patients are now living to an age at which the risk of...
WIB_icon

Investigating a Venetoclax-Based Triplet Therapy for Patients With Relapsed/Refractory Myeloma

Sunday, October 1st, 2017
In a phase Ib trial of patients with relapsed/refractory multiple myeloma, targeting BCL2 and MCL1 with a triplet combination of the BCL2 inhibitor venetoclax...

Luspatercept Shows Activity in Patients With Lower-Risk MDS and Anemia

Sunday, October 1st, 2017
Erythropoiesis-stimulating agents (ESAs) are a standard treatment for patients with myelodysplastic syndromes (MDS) and anemia; however, only around one-third of patients have an erythroid...

Using a Comorbidity-Based Composite Model to Predict Mortality in Patients With AML

Sunday, October 1st, 2017
Researchers developed a new composite model incorporating patient- and disease-specific features to predict mortality in patients with acute myeloid leukemia (AML), according to a...

Early Evidence Suggests PD-1 Inhibitors May Be Effective in Relapsed/Refractory Mediastinal Gray-Zone Lymphoma

Sunday, October 1st, 2017
Mediastinal gray-zone lymphoma, nodular sclerosis classic Hodgkin lymphoma (cHL), and primary mediastinal B-cell lymphoma have overlapping clinical, histologic, and molecular features, including the frequency...

ENDEAVOR: Carfilzomib Increases Overall Survival Over Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma

Sunday, October 1st, 2017
Previous results from the phase III ENDEAVOR study showed that treatment with the proteasome inhibitor carfilzomib plus dexamethasone extended progression-free survival (PFS) in patients...

SHARE